Caredx, Inc.
Brisbane, CA
- UEI
- Y371A27ZEUM4
- CAGE
- 53C84
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- West Chester, PA KHHBJ9FJR225
- ZWQHRE8M6QD6
- Caredx Transplant Management Inc. · Omaha, NE JW1HCXNLBEA7
-
- SAM.gov registration date
- Physical address
- 3260 Bayshore Blvd, Brisbane, CA 94005, USA
- Website
- caredx.com
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $64,815 |
| FY2026 | $7,049,230 |
| FY2025 | $4,924,263 |
| FY2024 | $1,196,376 |
| FY2023 | $2,529,643 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $7,114,045 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| High-specificity, non-invasive methods for monitoring lung transplants | National Institutes of Health | $267,693 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Eurofins Transplant Genomics, LLC | Lenexa, KS | 621511 Medical Laboratories |
| Natera Inc. | Austin, TX | 621511 Medical Laboratories |
| Biocartis US Inc. | Itasca, IL | 334516 Analytical Laboratory Instrument Manufacturing |
| Gendx Products LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mdxhealth, Inc. | Irvine, CA | 621511 Medical Laboratories |
About the company
Caredx, Inc., headquartered in Brisbane, California, is a for-profit medical diagnostics company that operates exclusively as a prime contractor delivering proprietary genetic and molecular transplant diagnostic testing services to the Department of Veterans Affairs across eleven distinct Veterans Integrated Service Networks (VISNs). The vendor competes full-and-open across its federal footprint; no set-aside categories characterize its prime portfolio, though the source notes that at least one subsidiary IDC vehicle was awarded under a small business set-aside designation. The company maintains a small organization with a focus on transplant rejection surveillance and post-transplant organ monitoring for veteran beneficiaries through proprietary test platforms — AlloMap gene expression profiling, AlloSure kidney and heart diagnostic tests, and related genetic blood testing services.
Caredx's federal capability portfolio centers narrowly on transplant diagnostics. Representative work includes a $2.5 million delivery order from VISN 12 awarded September 2026 for transplant testing kits (ultimate completion September 2027), a $1.6 million firm fixed-price delivery order from VISN 16 awarded April 2025 for post-transplant laboratory tests and organ rejection monitoring (ultimate completion March 2027), and a $1.25 million definitive contract from VISN 21 awarded March 2022 for AlloMap and AlloSure post-heart transplant rejection surveillance tests with a base period through February 2027 and four one-year option periods. The vendor also holds three named indefinite-delivery contracts: a $4.37 million single-award IDC with VISN 16 (April 2025–March 2030) for post-transplant laboratory testing, a $2.72 million single-award IDC with VISN 9 (September 2022–September 2027) for genetic blood testing services, and a $724,391 single-award IDC with VISN 23 (January 2025–January 2027) for in-home AlloSure patient testing that the VA determined Caredx supplies as sole source under NAICS 325413 and PSC 6640.
Customer concentration is extreme and deliberate. The top five VISNs account for 92% of combined potential value across 63 total awards. VISN 12 dominates at 13 awards and $16.1 million combined potential value; VISN 16 anchors the second-largest value share at 3 awards and $9.4 million; VISN 9 accounts for 11 awards and $8 million. All other VISN and federal customers (including the National Institutes of Health, Centers for Disease Control and Prevention, and Navy Bureau of Medicine and Surgery cited in award summaries) account for the remaining 8% of potential value. The concentration reflects Caredx's market position as the VA's standard transplant diagnostic vendor across regional networks rather than breadth of federal customer acquisition.
The vendor's activity trajectory shows flat-to-declining volume over the past five years (2022: 7 awards; 2023: 6 awards; 2024: 4 awards; 2025: 6 awards; 2026: 5 awards to date). Eight awards with combined potential value of $8.6 million reach ultimate completion within the next twenty-four months, creating corresponding recompete exposure. Combined potential value across all 63 awards stands at $40.3 million, with $21.1 million obligated (52% of potential value), indicating substantial optional or multiyear delivery order work not yet fully funded. The vendor operates without subcontractors across its federal footprint; all work is performed directly by Caredx or one of three named subsidiaries — Caredx Transplant Management Inc., Caredx Lab Solutions Inc. (noted as a manufacturer of goods), and Immumetrix, Inc.
The category concentration map shows the vendor's work clustered under medical laboratories (33 awards) and reference laboratory testing PSC codes (35 awards), with secondary activity in testing laboratories, biotechnology R&D, and in-vitro diagnostic substance manufacturing — a posture entirely aligned with transplant diagnostic service delivery. No set-aside recurrence, no subcontractor relationships, and 100% prime contractor status signal a specialized single-customer (Department of Veterans Affairs) market play anchored in clinical superiority and sole-source procurement justification rather than competitive differentiation or teaming strategy.
Quick answers
Is Caredx, Inc. registered in SAM.gov?
Yes. Caredx, Inc.'s SAM.gov registration is active through July 10, 2027.
How much has Caredx, Inc. received in federal contracts?
Federal contracts obligated $4,924,263 to Caredx, Inc. in fiscal year 2025 and $15,764,326 in fiscal years 2023 through 2027.
How does Caredx, Inc. rank among federal contractors?
Caredx, Inc. ranked #16 in NAICS 621511, #20 in NAICS 6215 and #21 in PSC AN41 in FY2025.
What is Caredx, Inc.'s most recent federal award?
Caredx, Inc.'s most recent federal contract award is Transplant testing kits (36C25226N0586), from Veterans Integrated Service Network 12 (VHA), on September 29, 2026.
On GovTribe
See Caredx, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors